A Tirzepatide Injection Once Weekly for the Treatment of Obesity

Tirzepatide – commonly known as Mounjaro™ – is FDA-approved for controlling diabetes similar to Semaglutide (also known as Ozempic®/Wegovy™). During clinical studies it has been shown the efficacy of Tirzepatide for weight loss.

In obesity cases the active ingredient Tirzepatide is being prescribed by doctors for weight loss. Tirzepatide produces weight loss by stimulating two satiety hormone receptors instead of just one with Semaglutide.

Maintenance Phase:

Month 2: Weeks 5-8, 5mg/5mg/0.5ml
Month 3: Weeks 9-12, 7.5mg/5mg/0.5ml
Month 4: Weeks 13-16, 10mg/5mg/0.5ml
Month 5: Weeks 17-20, 12.5mg/5mg/0.5ml
Month 6: Weeks 21-24, 15mg/5mg/0.5ml